- Messages
- 890
- Reaction score
- 2
- Points
- 0
This from e! Science News…
http://esciencenews.com/articles/20...g.therapy.uncontrolled.partial.onset.seizures
A recent multi-center study has confirmed earlier study results that 400 mg/day of Lacosamide (Vimpat) provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.
Researchers from the Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Thomas Jefferson University Medical School, Arkansas Epilepsy Program, Schwarz Biosciences and Johns Hopkins University Hospital conducted this study which is available early online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy…
Their findings were that Lacosamide is emerging as a promising candidate to reduce seizure frequency and severity with few adverse effects.
The efficacy and safety of adjunctive Lacosamide for partial-onset seizures was established in three multicenter, randomized, double-blind, placebo-controlled trials.
Results of the first trial indicated that study participants taking 400 and 600 mg/day of Lacosamide experienced significantly larger reductions in seizure frequency and significantly greater responder rates compared with placebo. Two additional phase III trials were conducted in parallel to confirm these results.
Study participants had at least a 2-year history of partial-onset seizures despite treatment with at least two AEDs (concurrently or sequentially) and were experiencing at least four partial-onset seizures per 28 days, with no seizure-free period longer than 21 days during the 8 weeks prior to baseline and during the 8-week baseline period.
Adjunct treatment with Lacosamide 400 and 600 mg/day was found to be effective in reducing the frequency of partial-onset seizures in patients with uncontrolled seizures while taking one to three AEDs concurrently.
“The efficacy results observed in this trial are notable given the epilepsy treatment history and the frequency of the seizures experienced by patients enrolled in this study.” Dr. Michael Sperling, one of the study authors, said. ”Despite this difficult-to-treat study population, treatment with Lacosamide 400 and 600 mg/day resulted in significant reductions from baseline in seizures, as well as significantly higher responder rates and a higher rate of seizure freedom compared with placebo—results that are comparable to established and second-generation AEDs.”
For further information about Lacosamide, go to the U.S. National Library of Medicine at the National Institutes of Health: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000506
http://esciencenews.com/articles/20...g.therapy.uncontrolled.partial.onset.seizures
A recent multi-center study has confirmed earlier study results that 400 mg/day of Lacosamide (Vimpat) provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.
Researchers from the Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Thomas Jefferson University Medical School, Arkansas Epilepsy Program, Schwarz Biosciences and Johns Hopkins University Hospital conducted this study which is available early online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy…
Their findings were that Lacosamide is emerging as a promising candidate to reduce seizure frequency and severity with few adverse effects.
The efficacy and safety of adjunctive Lacosamide for partial-onset seizures was established in three multicenter, randomized, double-blind, placebo-controlled trials.
Results of the first trial indicated that study participants taking 400 and 600 mg/day of Lacosamide experienced significantly larger reductions in seizure frequency and significantly greater responder rates compared with placebo. Two additional phase III trials were conducted in parallel to confirm these results.
Study participants had at least a 2-year history of partial-onset seizures despite treatment with at least two AEDs (concurrently or sequentially) and were experiencing at least four partial-onset seizures per 28 days, with no seizure-free period longer than 21 days during the 8 weeks prior to baseline and during the 8-week baseline period.
Adjunct treatment with Lacosamide 400 and 600 mg/day was found to be effective in reducing the frequency of partial-onset seizures in patients with uncontrolled seizures while taking one to three AEDs concurrently.
“The efficacy results observed in this trial are notable given the epilepsy treatment history and the frequency of the seizures experienced by patients enrolled in this study.” Dr. Michael Sperling, one of the study authors, said. ”Despite this difficult-to-treat study population, treatment with Lacosamide 400 and 600 mg/day resulted in significant reductions from baseline in seizures, as well as significantly higher responder rates and a higher rate of seizure freedom compared with placebo—results that are comparable to established and second-generation AEDs.”
For further information about Lacosamide, go to the U.S. National Library of Medicine at the National Institutes of Health: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000506